查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1539341

伽玛刀市场：2024-2032年全球产业分析、规模、占有率、成长、趋势、预测

Gamma Knife Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2032
出版日期: | 出版商: Persistence Market Research | 英文 102 Pages | 商品交期: 2-5个工作天内

价格
简介目录

Persistence Market Research 最近发布了一份关于全球伽玛刀市场的详细研究报告，提供了对市场动态（如驱动因素、趋势、机会和挑战）的详细见解。本报告目的是为医疗保健和医疗器材行业的利益相关者提供对市场结构和未来前景的全面了解，特别是关注非侵入性神经外科治疗。

关键见解

  • 全球市场收入（2022年）：2.041亿美元
  • 预计市场价值（2033年）：3.114亿美元
  • 全球市场成长率（2022-2033年年复合成长率）：4.8%

伽玛刀全球市场：研究范围

伽玛刀市场主要集中在伽玛刀机器的生产、分销和使用，伽玛刀机器是用于治疗脑肿瘤、血管畸形和其他神经系统疾病的非侵入性手术工具。该市场包括目的是透过精确放射外科手术改善患者治疗效果的广泛产品和服务，这些产品和服务能够在对周围健康组织影响最小的情况下治疗复杂的脑部疾病。

推动市场成长的因素：

脑肿瘤发生率上升及各种合併治疗简介

脑肿瘤发生率的上升和治疗方法的进步推动伽玛刀市场的成长。根据美国癌症协会的资料，脑肿瘤是 40 岁以上人口第八大常见癌症，也是第三大癌症死亡原因。随着世界人口老化和人口成长，对有效脑肿瘤治疗（包括伽玛刀放射外科手术）的需求预计将会增加。

伽玛刀放射手术是一种高度针对性的治疗方法，可以保留周围健康的脑组织，特别适合患有多发性脑转移的患者。伽玛刀放射外科与生物或免疫製剂结合也越来越受欢迎。例如，医科达针对黑色素瘤脑转移的联合疗法结合了免疫疗法和伽玛刀放射外科，显示出改善的肿瘤控制和患者生存率，凸显了联合疗法推动市场成长的潜力。

监理机关核准与新产品发布

监管部门的批准和创新产品的采用进一步支持了伽玛刀市场。例如，Elekta 于2022年 5月发布了 Icon。该伽玛刀系统透过提供无框架、基于面罩的放射外科手术彻底改变了这个领域。该系统在澳洲等地区特别受欢迎，扩大了大脑 SRS 治疗神经系统疾病的能力并推动了市场成长。

市场挑战：

伽玛刀放射治疗设备成本高，病患意识低

伽玛刀市场面临的主要挑战之一是伽玛刀设备的高成本以及相关的投资和维护成本。伽玛刀设备的初始成本明显高于其他辐射设备，限制了其在新兴国家的采用。例如，印度的伽玛刀手术起价为 6,500 美元，而在西方国家，费用在 40,000 美元至 70,000 美元之间。此外，伽玛刀装置中使用的钴60放射源的成本为100万美元至200万美元，并且必须每五年更换一次，增加了总体费用。

此外，美洲和欧洲以外地区伽玛刀设备的供应有限以及缺乏操作该设备的熟练专业人员也阻碍了市场成长。此外，大众对伽玛刀治疗的认识仍然较低，许多患者不知道其好处或对治疗有误解。这种意识和理解的缺乏预计将减缓市场成长，特别是在获得先进医疗技术的机会有限的地区。

本报告解决的关键问题

  • 推动全球伽玛刀市场成长的关键因素是什么？
  • 哪个消费族群引领伽玛刀治疗的采用？
  • 放射外科技术的进步如何影响竞争格局？
  • 谁是全球伽玛刀市场的主要参与者？ 他们采取哪些策略来维持其市场地位？
  • 全球伽玛刀市场的新趋势和未来前景是什么？

目录

第1章 执行摘要

第2章 市场概述

  • 市场范围/分类
  • 市场定义/范围/限制
  • 包含/排除

第3章 主要市场趋势

  • 影响市场的主要趋势
  • 产品创新/发展趋势

第4章 关键成功因素

  • 产品采用/使用分析
  • 产品 USP/特点
  • 安装基础场景
  • 技术评估
  • 监理状况
  • PESTLE分析
  • 波特分析
  • 价值链分析

第5章 市场背景

  • 宏观经济因素
  • 预测因子 - 相关性和影响
  • 动态

第6章 COVID-19 危机 - 影响评估

  • 新冠肺炎（COVID-19）与影响分析
    • 依疾病分类
    • 依治疗目标器官分类
    • 依地区
  • 2024年市场情景

第7章 全球市场需求（金额或规模，百万美元）分析

  • 2019-2023年过去的市值（百万美元）分析
  • 2024-2032年当前及未来市场价值（百万美元）预测
    • 年成长趋势分析
    • 绝对数量机会分析

第8章 全球市场分析：依疾病分类

  • 简介/主要发现
  • 2019-2023年历史市场规模（百万美元）分析：依疾病
  • 2024-2032年当前和未来市场规模（百万美元）的分析和预测：依疾病
    • 脑转移
    • 癌症
    • 动静脉畸形（AVM）
    • 三叉神经痛
    • 其他
  • 市场吸引力分析：依疾病分类

第9章 全球市场分析：依治疗器官

  • 简介/主要发现
  • 过去市场规模分析（百万美元）：依治疗器官，2019-2023年
  • 2024-2032年当前和未来市场规模（百万美元）分析和预测：依治疗器官
    • 头
    • 颈部
    • 其他
  • 市场吸引力分析：依治疗目标器官分类

第10章 世界市场分析：依地区

  • 简介
  • 2019-2023年历史市场规模分析（百万美元）：依地区
  • 2024-2032年当前和未来市场规模（百万美元）分析和预测：依地区
    • 北美
    • 拉丁美洲
    • 欧洲
    • 南亚
    • 东亚
    • 大洋洲
    • 中东和非洲（MEA）
  • 市场吸引力分析：依地区

第11章 北美市场分析

第12章 拉丁美洲市场分析

第13章 欧洲市场分析

第14章 南亚市场分析

第15章 东亚市场分析

第16章 大洋洲市场分析

第17章 中东、非洲市场分析

第18章 市场结构分析

  • 市场分析：依公司层级
  • 主要公司市占率分析
  • 市场现况分析

第19章 竞争分析

  • 竞争仪表板
  • 竞争基准
  • 竞争详情
    • Elekta AB
    • Varian Medical Systems
    • Huiheng Medical, Inc.
    • MASEP Medical Science Technology Development（Shenzhen）Co., Ltd.
    • Akesis Inc.
    • Cyber Medical Corporation Limited.
    • Masep Infini Global, Inc.
    • Nordion, Inc.
    • Hokai
    • ET Medical Group
    • American Shared Hospital Services

第20章 使用的先决条件与缩写

第21章 研究方法

简介目录
Product Code: PMRREP3742

Persistence Market Research has recently published an in-depth report on the global gamma knife market, offering detailed insights into market dynamics, including drivers, trends, opportunities, and challenges. This report aims to provide a comprehensive understanding of the market structure and future outlook, particularly for stakeholders in the healthcare and medical device sectors focused on non-invasive neurosurgical treatments.

Key Insights:

  • Global Market Revenue (2022): US$ 204.1 Million
  • Estimated Market Value (2033): US$ 311.4 Million
  • Global Market Growth Rate (CAGR 2022-2033): 4.8%

Global Gamma Knife Market - Report Scope:

The gamma knife market focuses on the production, distribution, and use of gamma knife machines, a non-invasive surgical tool primarily used for treating brain tumors, vascular malformations, and other neurological disorders. This market encompasses a range of products and services aimed at improving patient outcomes through precision radiosurgery, which allows for the treatment of complex brain conditions with minimal impact on surrounding healthy tissues.

Market Growth Drivers:

Rising Prevalence of Brain Tumors Coupled with Introduction of Various Combination Treatment Therapies

The rising incidence of brain tumors, coupled with advancements in treatment modalities, is driving the growth of the gamma knife market. According to the American Cancer Society, brain tumors are the eighth most prevalent type of cancer and the third leading cause of cancer deaths in people aged 40 and older. As the global population ages and expands, the demand for effective brain tumor treatments, including gamma knife radiosurgery, is expected to increase.

Gamma knife radiosurgery offers a highly targeted treatment option that spares surrounding healthy brain tissue, making it particularly suitable for patients with multiple brain metastases. The combination of gamma knife radiosurgery with biological and immunological agents is also gaining traction. For example, Elekta's combination therapy for melanoma brain metastases, which pairs immunotherapy with gamma knife radiosurgery, has shown improved tumor control and patient survival, highlighting the potential for combination treatments to drive market growth.

Regulatory Approvals and New Product Launches

The gamma knife market is further supported by regulatory approvals and the introduction of innovative products. For instance, Elekta introduced the Icon in May 2022, a gamma knife system that revolutionized the field by offering frameless, mask-based radiosurgery. This system has been particularly impactful in regions like Australia, where it has expanded the brain SRS capacity for treating neurological diseases, boosting market growth.

Market Challenges:

High Cost of Gamma Knife Radiotherapy Machines Coupled with Low Awareness of Patients

One of the significant challenges facing the gamma knife market is the high cost of gamma knife machines and the associated investment and maintenance expenses. The initial cost of gamma knife machines is considerably higher than other radiation equipment, which limits adoption in emerging economies. For instance, gamma knife surgery in India starts at USD 6,500, while in Western countries, the price ranges from USD 40,000 to USD 70,000. Additionally, the cobalt-60 radiation source used in gamma knife machines costs between USD 1 million to USD 2 million and requires replacement every five years, contributing to the overall expense.

The market's growth is also hindered by the limited availability of gamma knife machines outside of the Americas and Europe, as well as a shortage of skilled professionals capable of operating the equipment. Furthermore, general awareness of gamma knife treatment remains low, with many patients either unaware of the benefits or harboring misconceptions about the procedure. This lack of awareness and understanding is expected to slow down the market's growth, particularly in regions with limited access to advanced healthcare technologies.

Key Questions Answered in the Report:

  • What are the primary factors driving the growth of the global gamma knife market?
  • Which consumer segments are leading the adoption of gamma knife treatments?
  • How are advancements in radiosurgery technology influencing the competitive landscape?
  • Who are the key players in the global gamma knife market, and what strategies are they employing to maintain their market position?
  • What are the emerging trends and future prospects in the global gamma knife market?

Competitive Intelligence and Business Strategy:

Leading players in the global gamma knife market, such as Elekta AB, Varian Medical Systems, and Accuray Incorporated, are focusing on product innovation, strategic collaborations, and expanding their geographical presence to maintain a competitive edge. These companies are investing heavily in research and development to create advanced gamma knife systems that offer improved precision and patient outcomes. Collaborations with healthcare providers and government agencies are enhancing market credibility and driving the adoption of these technologies. Additionally, targeted marketing and educational campaigns are crucial for increasing patient awareness and acceptance of gamma knife treatments.

Key Companies Profiled:

  • Elekta AB
  • Varian Medical Systems
  • Huiheng Medical, Inc.
  • MASEP Medical Science Technology Development (Shenzhen) Co., Ltd.
  • Akesis Inc.
  • Cyber Medical Corporation Limited.
  • Masep Infini Global, Inc.
  • Nordion, Inc.
  • Hokai
  • ET Medical Group
  • American Shared Hospital Services

Key Segments Covered in Gamma Knife Industry Research

Disease Indication:

  • Brain Metastasis
  • Cancer
  • Arteriovenous Malformation (AVM)
  • Trigeminal Neuralgia
  • Others

Organ Treated:

  • Head
  • Neck
  • Others

Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Market Outlook
  • 1.2. Demand Side Trends
  • 1.3. Supply Side Trends
  • 1.4. Technology Roadmap
  • 1.5. Analysis and Recommendations

2. Market Overview

  • 2.1. Market Coverage / Taxonomy
  • 2.2. Market Definition / Scope / Limitations
  • 2.3. Inclusions and Exclusions

3. Key Market Trends

  • 3.1. Key Trends Impacting the Market
  • 3.2. Product Innovation / Development Trends

4. Key Success Factors

  • 4.1. Product Adoption / Usage Analysis
  • 4.2. Product USPs / Features
  • 4.3. Install Base Scenario
  • 4.4. Technology Assessment
  • 4.5. Regulatory Landscape
  • 4.6. PESTLE Analysis
  • 4.7. Porter Analysis
  • 4.8. Value Chain Analysis

5. Market Background

  • 5.1. Macro-Economic Factors
    • 5.1.1. Global GDP Growth Outlook
    • 5.1.2. Global Healthcare Expenditure Outlook
    • 5.1.3. Global Radiotherapy Market Outlook
  • 5.2. Forecast Factors - Relevance & Impact
    • 5.2.1. Prevalence of Obesity
    • 5.2.2. Demand for Non-Invasive Procedures
    • 5.2.3. Growing Burden of Brain Cancer
    • 5.2.4. Increasing Instances of Neurological Disorders
    • 5.2.5. Introduction of Novel Treatment Options
    • 5.2.6. Technological Advancements
    • 5.2.7. Product Adoption Rate
    • 5.2.8. Growing Installed Base
  • 5.3. Dynamics
    • 5.3.1. Drivers
    • 5.3.2. Restraints
    • 5.3.3. Opportunity Analysis

6. COVID-19 Crisis - Impact Assessment

  • 6.1. COVID-19 and Impact Analysis
    • 6.1.1. By Disease Indication
    • 6.1.2. By Organ Treated
    • 6.1.3. By Region
  • 6.2. 2024 Market Scenario

7. Global Market Demand (in Value or Size in US$ Mn) Analysis 2019-2023 and Forecast, 2024-2032

  • 7.1. Historical Market Value (US$ Mn) Analysis, 2019-2023
  • 7.2. Current and Future Market Value (US$ Mn) Projections, 2024-2032
    • 7.2.1. Y-o-Y Growth Trend Analysis
    • 7.2.2. Absolute $ Opportunity Analysis

8. Global Market Analysis 2019-2023 and Forecast 2024-2032, By Disease Indication

  • 8.1. Introduction / Key Findings
  • 8.2. Historical Market Size (US$ Mn) Analysis By Disease Indication, 2019-2023
  • 8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Disease Indication, 2024-2032
    • 8.3.1. Brain Metastasis
    • 8.3.2. Cancer
    • 8.3.3. Arteriovenous Malformation (AVM)
    • 8.3.4. Trigeminal Neuralgia
    • 8.3.5. Others
  • 8.4. Market Attractiveness Analysis By Disease Indication

9. Global Market Analysis 2019-2023 and Forecast 2024-2032, By Organ Treated

  • 9.1. Introduction / Key Findings
  • 9.2. Historical Market Size (US$ Mn) Analysis By Organ Treated, 2019-2023
  • 9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Organ Treated, 2024-2032
    • 9.3.1. Head
    • 9.3.2. Neck
    • 9.3.3. Others
  • 9.4. Market Attractiveness Analysis By Organ Treated

10. Global Market Analysis 2019-2023 and Forecast 2024-2032, by Region

  • 10.1. Introduction
  • 10.2. Historical Market Size (US$ Mn) Analysis By Region, 2019-2023
  • 10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Region, 2024-2032
    • 10.3.1. North America
    • 10.3.2. Latin America
    • 10.3.3. Europe
    • 10.3.4. South Asia
    • 10.3.5. East Asia
    • 10.3.6. Oceania
    • 10.3.7. Middle East and Africa (MEA)
  • 10.4. Market Attractiveness Analysis By Region

11. North America Market Analysis 2019-2023 and Forecast 2024-2032

  • 11.1. Introduction
  • 11.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
  • 11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2024-2032
    • 11.3.1. By Country
      • 11.3.1.1. U.S.
      • 11.3.1.2. Canada
    • 11.3.2. By Disease Indication
    • 11.3.3. By Organ Treated
  • 11.4. Market Attractiveness Analysis
    • 11.4.1. By Country
    • 11.4.2. By Disease Indication
    • 11.4.3. By Organ Treated
  • 11.5. Country Level Analysis & Forecast
    • 11.5.1. U.S. Market Analysis
      • 11.5.1.1. Introduction
      • 11.5.1.2. Market Analysis and Forecast by Market Taxonomy
        • 11.5.1.2.1. By Disease Indication
        • 11.5.1.2.2. By Organ Treated
    • 11.5.2. Canada Market Analysis
      • 11.5.2.1. Introduction
      • 11.5.2.2. Market Analysis and Forecast by Market Taxonomy
        • 11.5.2.2.1. By Disease Indication
        • 11.5.2.2.2. By Organ Treated
  • 11.6. Market Trends
  • 11.7. Key Market Participants - Intensity Mapping
  • 11.8. Drivers and Restraints - Impact Analysis

12. Latin America Market Analysis 2019-2023 and Forecast 2024-2032

  • 12.1. Introduction
  • 12.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
  • 12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2024-2032
    • 12.3.1. By Country
      • 12.3.1.1. Brazil
      • 12.3.1.2. Mexico
      • 12.3.1.3. Argentina
      • 12.3.1.4. Rest of Latin America
    • 12.3.2. By Disease Indication
    • 12.3.3. By Organ Treated
  • 12.4. Market Attractiveness Analysis
    • 12.4.1. By Country
    • 12.4.2. By Disease Indication
    • 12.4.3. By Organ Treated
  • 12.5. Country Level Analysis & Forecast
    • 12.5.1. Brazil Market Analysis
      • 12.5.1.1. Introduction
      • 12.5.1.2. Market Analysis and Forecast by Market Taxonomy
        • 12.5.1.2.1. By Disease Indication
        • 12.5.1.2.2. By Organ Treated
    • 12.5.2. Mexico Market Analysis
      • 12.5.2.1. Introduction
      • 12.5.2.2. Market Analysis and Forecast by Market Taxonomy
        • 12.5.2.2.1. By Disease Indication
        • 12.5.2.2.2. By Organ Treated
    • 12.5.3. Argentina Market Analysis
      • 12.5.3.1. Introduction
      • 12.5.3.2. Market Analysis and Forecast by Market Taxonomy
        • 12.5.3.2.1. By Disease Indication
        • 12.5.3.2.2. By Organ Treated
  • 12.6. Market Trends
  • 12.7. Key Market Participants - Intensity Mapping
  • 12.8. Drivers and Restraints - Impact Analysis

13. Europe Market Analysis 2019-2023 and Forecast 2024-2032

  • 13.1. Introduction
  • 13.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
  • 13.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2024-2032
    • 13.3.1. By Country
      • 13.3.1.1. Germany
      • 13.3.1.2. France
      • 13.3.1.3. Italy
      • 13.3.1.4. U.K.
      • 13.3.1.5. Spain
      • 13.3.1.6. Russia
      • 13.3.1.7. BENELUX
      • 13.3.1.8. Nordic Countries
      • 13.3.1.9. Rest of Europe
    • 13.3.2. By Disease Indication
    • 13.3.3. By Organ Treated
  • 13.4. Market Attractiveness Analysis
    • 13.4.1. By Country
    • 13.4.2. By Disease Indication
    • 13.4.3. By Organ Treated
  • 13.5. Country Level Analysis & Forecast
    • 13.5.1. Germany Market Analysis
      • 13.5.1.1. Introduction
      • 13.5.1.2. Market Analysis and Forecast by Market Taxonomy
        • 13.5.1.2.1. By Disease Indication
        • 13.5.1.2.2. By Organ Treated
    • 13.5.2. France Market Analysis
      • 13.5.2.1. Introduction
      • 13.5.2.2. Market Analysis and Forecast by Market Taxonomy
        • 13.5.2.2.1. By Disease Indication
        • 13.5.2.2.2. By Organ Treated
    • 13.5.3. Italy Market Analysis
      • 13.5.3.1. Introduction
      • 13.5.3.2. Market Analysis and Forecast by Market Taxonomy
        • 13.5.3.2.1. By Disease Indication
        • 13.5.3.2.2. By Organ Treated
    • 13.5.4. U.K. Market Analysis
      • 13.5.4.1. Introduction
      • 13.5.4.2. Market Analysis and Forecast by Market Taxonomy
        • 13.5.4.2.1. By Disease Indication
        • 13.5.4.2.2. By Organ Treated
    • 13.5.5. Spain Market Analysis
      • 13.5.5.1. Introduction
      • 13.5.5.2. Market Analysis and Forecast by Market Taxonomy
        • 13.5.5.2.1. By Disease Indication
        • 13.5.5.2.2. By Organ Treated
    • 13.5.6. Russia Market Analysis
      • 13.5.6.1. Introduction
      • 13.5.6.2. Market Analysis and Forecast by Market Taxonomy
        • 13.5.6.2.1. By Disease Indication
        • 13.5.6.2.2. By Organ Treated
    • 13.5.7. Nordic Countries Market Analysis
      • 13.5.7.1. Introduction
      • 13.5.7.2. Market Analysis and Forecast by Market Taxonomy
        • 13.5.7.2.1. By Disease Indication
        • 13.5.7.2.2. By Organ Treated
    • 13.5.8. BENELUX Market Analysis
      • 13.5.8.1. Introduction
      • 13.5.8.2. Market Analysis and Forecast by Market Taxonomy
        • 13.5.8.2.1. By Disease Indication
        • 13.5.8.2.2. By Organ Treated
  • 13.6. Market Trends
  • 13.7. Key Market Participants - Intensity Mapping
  • 13.8. Drivers and Restraints - Impact Analysis

14. South Asia Market Analysis 2019-2023 and Forecast 2024-2032

  • 14.1. Introduction
  • 14.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
  • 14.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2024-2032
    • 14.3.1. By Country
      • 14.3.1.1. India
      • 14.3.1.2. Thailand
      • 14.3.1.3. Indonesia
      • 14.3.1.4. Malaysia
      • 14.3.1.5. Rest of South Asia
    • 14.3.2. By Disease Indication
    • 14.3.3. By Organ Treated
  • 14.4. Market Attractiveness Analysis
    • 14.4.1. By Country
    • 14.4.2. By Disease Indication
    • 14.4.3. By Organ Treated
  • 14.5. Country Level Analysis & Forecast
    • 14.5.1. India Market Analysis
      • 14.5.1.1. Introduction
      • 14.5.1.2. Market Analysis and Forecast by Market Taxonomy
        • 14.5.1.2.1. By Disease Indication
        • 14.5.1.2.2. By Organ Treated
    • 14.5.2. Thailand Market Analysis
      • 14.5.2.1. Introduction
      • 14.5.2.2. Market Analysis and Forecast by Market Taxonomy
        • 14.5.2.2.1. By Disease Indication
        • 14.5.2.2.2. By Organ Treated
    • 14.5.3. Indonesia Market Analysis
      • 14.5.3.1. Introduction
      • 14.5.3.2. Market Analysis and Forecast by Market Taxonomy
        • 14.5.3.2.1. By Disease Indication
        • 14.5.3.2.2. By Organ Treated
    • 14.5.4. Malaysia Market Analysis
      • 14.5.4.1. Introduction
      • 14.5.4.2. Market Analysis and Forecast by Market Taxonomy
        • 14.5.4.2.1. By Disease Indication
        • 14.5.4.2.2. By Organ Treated
  • 14.6. Market Trends
  • 14.7. Key Market Participants - Intensity Mapping
  • 14.8. Drivers and Restraints - Impact Analysis

15. East Asia Market Analysis 2019-2023 and Forecast 2024-2032

  • 15.1. Introduction
  • 15.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
  • 15.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2024-2032
    • 15.3.1. By Country
      • 15.3.1.1. China
      • 15.3.1.2. Japan
      • 15.3.1.3. South Korea
    • 15.3.2. By Disease Indication
    • 15.3.3. By Organ Treated
  • 15.4. Market Attractiveness Analysis
    • 15.4.1. By Country
    • 15.4.2. By Disease Indication
    • 15.4.3. By Organ Treated
  • 15.5. Country Level Analysis & Forecast
    • 15.5.1. China Market Analysis
      • 15.5.1.1. Introduction
      • 15.5.1.2. Market Analysis and Forecast by Market Taxonomy
        • 15.5.1.2.1. By Disease Indication
        • 15.5.1.2.2. By Organ Treated
    • 15.5.2. Japan Market Analysis
      • 15.5.2.1. Introduction
      • 15.5.2.2. Market Analysis and Forecast by Market Taxonomy
        • 15.5.2.2.1. By Disease Indication
        • 15.5.2.2.2. By Organ Treated
    • 15.5.3. South Korea Market Analysis
      • 15.5.3.1. Introduction
      • 15.5.3.2. Market Analysis and Forecast by Market Taxonomy
        • 15.5.3.2.1. By Disease Indication
        • 15.5.3.2.2. By Organ Treated
  • 15.6. Market Trends
  • 15.7. Key Market Participants - Intensity Mapping
  • 15.8. Drivers and Restraints - Impact Analysis

16. Oceania Market Analysis 2019-2023 and Forecast 2024-2032

  • 16.1. Introduction
  • 16.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
  • 16.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2024-2032
    • 16.3.1. By Country
      • 16.3.1.1. Australia
      • 16.3.1.2. New Zealand
    • 16.3.2. By Disease Indication
    • 16.3.3. By Organ Treated
  • 16.4. Market Attractiveness Analysis
    • 16.4.1. By Country
    • 16.4.2. By Disease Indication
    • 16.4.3. By Organ Treated
  • 16.5. Country Level Analysis & Forecast
    • 16.5.1. Australia Market Analysis
      • 16.5.1.1. Introduction
      • 16.5.1.2. Market Analysis and Forecast by Market Taxonomy
        • 16.5.1.2.1. By Disease Indication
        • 16.5.1.2.2. By Organ Treated
    • 16.5.2. New Zealand Market Analysis
      • 16.5.2.1. Introduction
      • 16.5.2.2. Market Analysis and Forecast by Market Taxonomy
        • 16.5.2.2.1. By Disease Indication
        • 16.5.2.2.2. By Organ Treated
  • 16.6. Market Trends
  • 16.7. Key Market Participants - Intensity Mapping
  • 16.8. Drivers and Restraints - Impact Analysis

17. Middle East and Africa Market Analysis 2019-2023 and Forecast 2024-2032

  • 17.1. Introduction
  • 17.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
  • 17.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2024-2032
    • 17.3.1. By Country
      • 17.3.1.1. GCC Countries
      • 17.3.1.2. Turkiye
      • 17.3.1.3. Northern Africa
      • 17.3.1.4. South Africa
      • 17.3.1.5. Rest of Middle East and Africa
    • 17.3.2. By Disease Indication
    • 17.3.3. By Organ Treated
  • 17.4. Market Attractiveness Analysis
    • 17.4.1. By Country
    • 17.4.2. By Disease Indication
    • 17.4.3. By Organ Treated
  • 17.5. Country Level Analysis & Forecast
    • 17.5.1. GCC Countries Market Analysis
      • 17.5.1.1. Introduction
      • 17.5.1.2. Market Analysis and Forecast by Market Taxonomy
        • 17.5.1.2.1. By Disease Indication
        • 17.5.1.2.2. By Organ Treated
    • 17.5.2. Turkiye Market Analysis
      • 17.5.2.1. Introduction
      • 17.5.2.2. Market Analysis and Forecast by Market Taxonomy
        • 17.5.2.2.1. By Disease Indication
        • 17.5.2.2.2. By Organ Treated
    • 17.5.3. Northern Africa Market Analysis
      • 17.5.3.1. Introduction
      • 17.5.3.2. Market Analysis and Forecast by Market Taxonomy
        • 17.5.3.2.1. By Disease Indication
        • 17.5.3.2.2. By Organ Treated
    • 17.5.4. South Africa Market Analysis
      • 17.5.4.1. Introduction
      • 17.5.4.2. Market Analysis and Forecast by Market Taxonomy
        • 17.5.4.2.1. By Disease Indication
        • 17.5.4.2.2. By Organ Treated
  • 17.6. Market Trends
  • 17.7. Key Market Participants - Intensity Mapping
  • 17.8. Drivers and Restraints - Impact Analysis

18. Market Structure Analysis

  • 18.1. Market Analysis by Tier of Companies
  • 18.2. Market Share Analysis of Top Players
  • 18.3. Market Presence Analysis

19. Competition Analysis

  • 19.1. Competition Dashboard
  • 19.2. Competition Benchmarking
  • 19.3. Competition Deep Dive
    • 19.3.1. Elekta AB
      • 19.3.1.1. Overview
      • 19.3.1.2. Disease Indication Portfolio
      • 19.3.1.3. Key Financials
      • 19.3.1.4. Sales Footprint
      • 19.3.1.5. SWOT Analysis
      • 19.3.1.6. Strategy Overview
        • 19.3.1.6.1. Marketing Strategy
        • 19.3.1.6.2. Product Strategy
        • 19.3.1.6.3. Channel Strategy
    • 19.3.2. Varian Medical Systems
      • 19.3.2.1. Overview
      • 19.3.2.2. Disease Indication Portfolio
      • 19.3.2.3. Key Financials
      • 19.3.2.4. Sales Footprint
      • 19.3.2.5. SWOT Analysis
      • 19.3.2.6. Strategy Overview
        • 19.3.2.6.1. Marketing Strategy
        • 19.3.2.6.2. Product Strategy
        • 19.3.2.6.3. Channel Strategy
    • 19.3.3. Huiheng Medical, Inc.
      • 19.3.3.1. Overview
      • 19.3.3.2. Disease Indication Portfolio
      • 19.3.3.3. Key Financials
      • 19.3.3.4. Sales Footprint
      • 19.3.3.5. SWOT Analysis
      • 19.3.3.6. Strategy Overview
        • 19.3.3.6.1. Marketing Strategy
        • 19.3.3.6.2. Product Strategy
        • 19.3.3.6.3. Channel Strategy
    • 19.3.4. MASEP Medical Science Technology Development (Shenzhen) Co., Ltd.
      • 19.3.4.1. Overview
      • 19.3.4.2. Disease Indication Portfolio
      • 19.3.4.3. Key Financials
      • 19.3.4.4. Sales Footprint
      • 19.3.4.5. SWOT Analysis
      • 19.3.4.6. Strategy Overview
        • 19.3.4.6.1. Marketing Strategy
        • 19.3.4.6.2. Product Strategy
        • 19.3.4.6.3. Channel Strategy
    • 19.3.5. Akesis Inc.
      • 19.3.5.1. Overview
      • 19.3.5.2. Disease Indication Portfolio
      • 19.3.5.3. Key Financials
      • 19.3.5.4. Sales Footprint
      • 19.3.5.5. SWOT Analysis
      • 19.3.5.6. Strategy Overview
        • 19.3.5.6.1. Marketing Strategy
        • 19.3.5.6.2. Product Strategy
        • 19.3.5.6.3. Channel Strategy
    • 19.3.6. Cyber Medical Corporation Limited.
      • 19.3.6.1. Overview
      • 19.3.6.2. Disease Indication Portfolio
      • 19.3.6.3. Key Financials
      • 19.3.6.4. Sales Footprint
      • 19.3.6.5. SWOT Analysis
      • 19.3.6.6. Strategy Overview
        • 19.3.6.6.1. Marketing Strategy
        • 19.3.6.6.2. Product Strategy
        • 19.3.6.6.3. Channel Strategy
    • 19.3.7. Masep Infini Global, Inc.
      • 19.3.7.1. Overview
      • 19.3.7.2. Disease Indication Portfolio
      • 19.3.7.3. Key Financials
      • 19.3.7.4. Sales Footprint
      • 19.3.7.5. SWOT Analysis
      • 19.3.7.6. Strategy Overview
        • 19.3.7.6.1. Marketing Strategy
        • 19.3.7.6.2. Product Strategy
        • 19.3.7.6.3. Channel Strategy
    • 19.3.8. Nordion, Inc.
      • 19.3.8.1. Overview
      • 19.3.8.2. Disease Indication Portfolio
      • 19.3.8.3. Key Financials
      • 19.3.8.4. Sales Footprint
      • 19.3.8.5. SWOT Analysis
      • 19.3.8.6. Strategy Overview
        • 19.3.8.6.1. Marketing Strategy
        • 19.3.8.6.2. Product Strategy
        • 19.3.8.6.3. Channel Strategy
    • 19.3.9. Hokai
      • 19.3.9.1. Overview
      • 19.3.9.2. Disease Indication Portfolio
      • 19.3.9.3. Key Financials
      • 19.3.9.4. Sales Footprint
      • 19.3.9.5. SWOT Analysis
      • 19.3.9.6. Strategy Overview
        • 19.3.9.6.1. Marketing Strategy
        • 19.3.9.6.2. Product Strategy
        • 19.3.9.6.3. Channel Strategy
    • 19.3.10. ET Medical Group
      • 19.3.10.1. Overview
      • 19.3.10.2. Disease Indication Portfolio
      • 19.3.10.3. Key Financials
      • 19.3.10.4. Sales Footprint
      • 19.3.10.5. SWOT Analysis
      • 19.3.10.6. Strategy Overview
        • 19.3.10.6.1. Marketing Strategy
        • 19.3.10.6.2. Product Strategy
        • 19.3.10.6.3. Channel Strategy
    • 19.3.11. American Shared Hospital Services
      • 19.3.11.1. Overview
      • 19.3.11.2. Disease Indication Portfolio
      • 19.3.11.3. Key Financials
      • 19.3.11.4. Sales Footprint
      • 19.3.11.5. SWOT Analysis
      • 19.3.11.6. Strategy Overview
        • 19.3.11.6.1. Marketing Strategy
        • 19.3.11.6.2. Product Strategy
        • 19.3.11.6.3. Channel Strategy

20. Assumptions and Acronyms Used

21. Research Methodology